Treatment of hepatocellular carcinoma during the COVID-19 outbreak: The Working Group report of JAMTT-HCC
Treatment of hepatocellular carcinoma during the COVID-19 outbreak: The Working Group report of JAMTT-HCC
复制标题
DOI：
10.1111/hepr.13541
复制
发表时间：
2020-07-20
影响因子：
4.2
通讯作者：
Sakamoto, Naoya
中科院分区：
文献类型：
--
作者：
Kudo, Masatoshi;Kurosaki, Masayuki;Sakamoto, Naoya
本应急指南的制定前提是，由于冠状病毒 (COVID-19) 大流行，肝细胞癌 (HCC) 的标准治疗面临压力。不同地区和各个机构所需采取的措施可能会有很大差异，具体取决于大流行造成的压力程度（例如，感染 COVID-19 的住院患者数量以及资源的可用性，包括个人防护设备和住院床位）。此外，模型表明，在有效的疫苗和药物在日本广泛使用之前，第二波和第三波 COVID-19 将发生（预计时间为 2-3 年）。鉴于 COVID-19 感染激增可能导致医疗保健系统面临崩溃的风险，本指南应作为 HCC 管理最佳实践的良好参考。
This contingency guide was formulated on the premise that delivering standard treatment for hepatocellular carcinoma (HCC) has come under strain due to the coronavirus (COVID-19) pandemic. Measures required are likely to vary largely across regions and individual institutions, depending on the level of the strain imposed by the pandemic (e.g., number of inpatients infected with COVID-19 and the availability of resources, including personal protective equipment and inpatient beds). In addition, models suggest that the second and third waves of COVID-19 will occur before effective vaccines and medicines become widely available in Japan (expected time, 2-3 years). This guide should serve as a good reference for best practices in the management of HCC, which is in light of the possible risk of impending collapse of the healthcare system due to a surge in COVID-19 infections.